Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Citryll

Request full access

Develops therapeutics targeting the neutrophil extracellular trap (NET) pathway to treat inflammatory diseases, with its lead antibody, CIT-013, in clinical trials for rheumatoid arthritis and…

Oss, NetherlandsFounded 2015Biotech & Life Sciences

About Citryll

Citryll is a Dutch biotech company focused on developing innovative treatments for autoimmune and other severe diseases such as lupus, vasculitis, pulmonary fibrosis, asthma, rheumatoid arthritis, and organ damage due to sepsis. The company targets the pathobiology of neutrophil extracellular traps (NETs), which are networks of extracellular fibers composed of DNA from neutrophils, a type of white blood cell. By inhibiting the source of autoantigens and NET-derived toxic molecules, Citryll aims to provide a more targeted approach to treatment, avoiding the broad targeting of inflammation or acquired immunity.

Citryll operates in the biopharmaceutical market, primarily serving patients with autoimmune and inflammatory diseases. The company's business model involves the research, development, and commercialization of therapeutic antibodies. Citryll makes money through the development and eventual sale of its proprietary treatments, as well as potential partnerships and licensing agreements with larger pharmaceutical companies.

Citryll's lead product, CIT-013, is currently in the development phase, with first human dosing planned as part of a Single Ascending Dose (SAD) study in healthy volunteers. The company collaborates with partners like Lonza for GMP production and formulation of the antibody.

Source: Dealroom company data

At a glance

Status
Operational
Employees
39
Open positions
None listed
Dealroom signal
87.6/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Neurology, Autoimmune, Inflammatory Diseases, Biotech and Pharma, Seal of Excellence EC, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES BOther financing Dec 2024 $94M $374M BioGeneration Ventures · BOM - Brabant Regional Development Agency · Pureos Bioventures · Curie Capital ↗
EARLY VCOther financing Jul 2020 $20M $81M BrightGene · Seventure Partners · BioGeneration Ventures · BOM - Brabant Regional Development Agency —
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Citryll website traffic

Latest recorded traffic for Citryll is 1.4K monthly website visits, up 0% over the last three months. Citryll's team grew 21.9% over the past year.

Latest monthly visits1.4K 3-month web change0% 1-year team growth+21.9%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Citryll in the Oss ecosystem

Live from Dealroom

The Citryll office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

10 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A10 investors entered at this stage

  • BOM - Brabant Regional Development Agency
  • ModiQuest
  • BrightGene
  • Seventure Partners
  • BioGeneration Ventures
  • Johnson & Johnson Innovation
  • Novartis Venture Fund
  • Forbion Capital Partners
  • Pureos Bioventures
  • Curie Capital
Team profiled 11 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 6 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

See Citryll’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.